Developer docs
API playgroundTry for free, no card

Search company profiles

IO Biotech

Full company profile

uuid000034q

Namestring
IO Biotech
Legal namestring
IO Biotech, Inc.
Websiteurl
iobiotech.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

IO Biotech was a clinical-stage biopharmaceutical company that developed immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win platform. Founded in 2014 in Copenhagen, Denmark, the company's T-win technology delivers peptide epitopes from immune-suppressive antigens (IDO1, PD-L1, arginase-1, and TGF-β) to activate and expand T cells that target both tumor cells and immune-suppressive cells in the tumor microenvironment, creating a pro-inflammatory milieu that potentiates anti-tumor activity. The lead candidate, Cylembio (IO102-IO103, imsapepimut and etimupepimut adjuvanted), combined vaccines targeting IDO1 and PD-L1 and was evaluated in combination with Merck's pembrolizumab (Keytruda) for first-line treatment of advanced melanoma, NSCLC, and head and neck cancers. The pipeline also included IO112 (arginase-1) and IO170 (TGF-β1) vaccine candidates.

The company operated under a clinical-stage business model with no product revenue, funded by capital markets and debt. IO Biotech completed a €127 million Series B in January 2021, an approximately $75 million private placement in August 2023, and up to €57.5 million in debt financing from the European Investment Bank announced in December 2024. The company completed its IPO on NASDAQ under ticker IOBT in November 2021, retaining global commercial rights to Cylembio and planning for a U.S. launch. The Phase 3 IOB-013/KN-D18 trial enrolled 407 patients across more than 100 sites in the US, Europe, Australia, Turkey, Israel, and South Africa, with pembrolizumab supplied by Merck under a clinical collaboration. Reported Phase 1/2 data included 80% objective response rate and 25.5-month median progression-free survival at five-year follow-up, published in Nature Medicine and Nature Communications.

In August 2025, the company announced Phase 3 results showing 19.4 months median PFS for Cylembio plus pembrolizumab versus 11.0 months for pembrolizumab alone, with a 23% reduction in risk of disease progression or death (HR 0.77) but a p-value of 0.056, narrowly missing statistical significance. In September 2025, the FDA recommended against BLA submission, prompting approximately 50% workforce reductions. The company engaged Raymond James in January 2026 to explore strategic alternatives and ultimately filed for Chapter 7 bankruptcy in March 2026, ceasing all operations with all directors stepping down and shareholders unlikely to receive liquidation proceeds.

Short descriptiontext

IO Biotech was a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines using its T-win platform, with lead candidate Cylembio for advanced melanoma. The company filed for Chapter 7 bankruptcy in March 2026 after the FDA rejected its BLA.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic cancer vaccines, immune oncology, tumor microenvironment modulation, off-the-shelf peptide vaccines, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Revenue (Future)
TypeOne Time License
Description

Pre-commercial stage company. Planned U.S. product launch for Cylembio was expected in 2026 prior to FDA rejection. No revenue currently generated from product sales.

iobiotech.com
2Debt Financing
TypeLicensing Royalties
Description

European Investment Bank debt financing of up to €57.5 million to fund development of cancer vaccine candidates, with first disbursements expected in early 2025.

citybiz.co
3Private Placement Financing
TypeSubscription Recurring
Description

$75 million private placement financing involving new and existing investors to support ongoing clinical trials, extending cash runway into late 2025.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1T-win
Description

The company's proprietary immune-modulatory vaccine technology platform designed to activate T cells to target both tumor cells and immune-suppressive cells in the tumor microenvironment.

iobiotech.com
+1 more record
Core offering1 text field

IO Biotech develops off-the-shelf, immune-modulatory therapeutic cancer vaccines built on its proprietary T-win® platform. Lead candidate Cylembio (IO102-IO103 / imsapepimut and etimupepimut, adjuvanted) combines peptide epitopes targeting IDO1 and PD-L1 and was evaluated in combination with pembrolizumab in a global Phase 3 trial for advanced melanoma, with additional Phase 2 studies in NSCLC and head and neck cancer. Pipeline candidates IO112 (arginase-1) and IO170 (TGF-βL1) extend the platform to other immune-suppressive pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 19.4 months median progression-free survival (mPFS) vs 11.0 months for pembrolizumab alone in Phase 3 trial
+4 more records
Product overview1 text field

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win® platform. The company's lead product candidate is Cylembio (imsapepimut and etimupepimut, adjuvanted), also known as IO102-IO103, which combines two vaccines targeting IDO1 and PD-L1. The pipeline includes additional candidates IO112 (arginase-1 targeting) and IO170 (TGF-β targeting), all leveraging the T-win platform's dual mechanism of action to kill tumor cells and immune-suppressive cells in the tumor microenvironment.

Product and service3 records
1Cylembio (imsapepimut and etimupepimut, adjuvanted; also known as IO102-IO103)
CategoryInvestigational therapeutic cancer vaccine
Description

Cylembio (IO102-IO103) is IO Biotech's lead investigational immune-modulatory, off-the-shelf therapeutic cancer vaccine combining two vaccine components: IO102 targeting the IDO1 immune-suppressive antigen and IO103 targeting PD-L1. It is designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment by stimulating T cell activation against IDO1+ and/or PD-L1+ cells, with intended use in combination with pembrolizumab for advanced melanoma, NSCLC, and head and neck cancer.

2IO112 (Arginase-1 Vaccine)
CategoryInvestigational therapeutic cancer vaccine (pipeline candidate)
Description

IO112 is a wholly owned IO Biotech T-win vaccine candidate designed to activate and expand T cells specific for arginase-1 positive/expressing cells in the tumor microenvironment. Arginase-1 is highly expressed in difficult-to-treat tumors including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal and prostate cancers, positioning IO112 as a potential pipeline candidate for these indications.

3IO170 (TGF-βL1 Vaccine)
CategoryInvestigational therapeutic cancer vaccine (pipeline candidate)
Description

IO170 is a novel T-win immune-modulatory therapeutic cancer vaccine candidate designed to target TGF-βL1-expressing cells in the tumor microenvironment. By stimulating T cell activity against TGF-βL1+ cells, the vaccine aims to modulate the TGF-β pathway and drive therapeutic benefit across tumors dependent on TGF-β signaling.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Clinical collaboration with Merck (known as MSD outside US and Canada) to evaluate IO102-IO103 in combination with KEYTRUDA (pembrolizumab). Merck supplies pembrolizumab for clinical trials while IO Biotech sponsors the trials and maintains global commercial rights. Partnership includes Phase 3 trial (IOB-013/KN-D18) in advanced melanoma and Phase 2 basket trials in lung and head/neck cancers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Investigator-initiated trial (MM1636) conducted at Copenhagen University Hospital, Herlev. Scientific co-founders Dr. Mads Hald Andersen and Dr. Inge Marie Svane serve at this institution. Publication of five-year outcomes in Nature Communications.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Moderna is developing mRNA-based therapeutic cancer vaccines, including personalized neoantigen programs (mRNA-4157) in melanoma in combination with Merck's pembrolizumab. Directly comparable as a clinical-stage therapeutic cancer vaccine developer targeting the same checkpoint-inhibitor combination space as IO Biotech's Cylembio.

TypeDirect peer
Description

BioNTech is a leading mRNA cancer vaccine developer with FixVac (off-the-shelf shared-antigen) and individualized neoantigen programs across melanoma and other solid tumors. Closely comparable to IO Biotech's off-the-shelf, immune-modulatory vaccine approach with multiple clinical-stage candidates.

TypeDirect peer
Description

Gritstone bio developed neoantigen cancer vaccines (GRANITE, SLATE) and similarly pursued first-line metastatic melanoma combinations with checkpoint inhibitors. It filed for bankruptcy in 2024 after a Phase 2 failure, making it a highly comparable cautionary precedent for IO Biotech's trajectory.

TypeDirect peer
Description

Bavarian Nordic develops therapeutic cancer vaccines including its CV301 platform targeting CEA and MUC1 antigens in combination with checkpoint inhibitors. Comparable as a clinical-to-commercial stage developer of off-the-shelf therapeutic cancer vaccines in oncology.

TypeEmerging player
Description

Nouscom is a privately held biotech developing off-the-shelf, vector-based neoantigen cancer vaccines in solid tumors. Comparable emerging-stage therapeutic cancer vaccine developer using a similar off-the-shelf, combination-therapy approach as IO Biotech's Cylembio.

6Transgene
TypeDirect peer
Description

Transgene is a French clinical-stage biotech developing therapeutic cancer vaccines using viral-vector technology (TG4050 individualized neoantigen vaccine and TG4001 HPV-targeted). Comparable as a clinical-stage developer of therapeutic cancer vaccines often combined with checkpoint inhibitors.

TypeDirect peer
Description

Northwest Biotherapeutics develops DCVax, a dendritic cell-based therapeutic cancer vaccine platform for glioblastoma and other solid tumors. Comparable as a clinical-stage developer of immune-cell-based therapeutic cancer vaccines targeting solid tumors.

TypeDirect peer
Description

VBI Vaccines is a clinical-stage biotech developing immunotherapeutic vaccines including eVLP-based candidates for oncology indications. Comparable as a clinical-stage therapeutic vaccine developer operating in the immune-oncology space.

TypeBroad incumbent
Description

Merck is the maker of Keytruda (pembrolizumab), the checkpoint inhibitor used as both the combination partner and comparator in IO Biotech's Phase 3 trial. It is also a broader incumbent in immuno-oncology with a deep oncology pipeline and was IO Biotech's clinical-trial partner under a 2022 collaboration.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb is a broad incumbent in immuno-oncology with Opdivo (nivolumab) and Yervoy (ipilimumab) as foundational checkpoint inhibitors. Comparable as a leading competitor defining the treatment landscape IO Biotech's Cylembio sought to enter in first-line melanoma.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles22 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IO Biotech

Oncology Biopharmaceuticalsiobiotech.com

IO Biotech was a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines using its T-win platform, with lead candidate Cylembio for advanced melanoma. The company filed for Chapter 7 bankruptcy in March 2026 after the FDA rejected its BLA.

What IO Biotech does

IO Biotech was a clinical-stage biopharmaceutical company that developed immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win platform. Founded in 2014 in Copenhagen, Denmark, the company's T-win technology delivers peptide epitopes from immune-suppressive antigens (IDO1, PD-L1, arginase-1, and TGF-β) to activate and expand T cells that target both tumor cells and immune-suppressive cells in the tumor microenvironment, creating a pro-inflammatory milieu that potentiates anti-tumor activity. The lead candidate, Cylembio (IO102-IO103, imsapepimut and etimupepimut adjuvanted), combined vaccines targeting IDO1 and PD-L1 and was evaluated in combination with Merck's pembrolizumab (Keytruda) for first-line treatment of advanced melanoma, NSCLC, and head and neck cancers. The pipeline also included IO112 (arginase-1) and IO170 (TGF-β1) vaccine candidates.

The company operated under a clinical-stage business model with no product revenue, funded by capital markets and debt. IO Biotech completed a €127 million Series B in January 2021, an approximately $75 million private placement in August 2023, and up to €57.5 million in debt financing from the European Investment Bank announced in December 2024. The company completed its IPO on NASDAQ under ticker IOBT in November 2021, retaining global commercial rights to Cylembio and planning for a U.S. launch. The Phase 3 IOB-013/KN-D18 trial enrolled 407 patients across more than 100 sites in the US, Europe, Australia, Turkey, Israel, and South Africa, with pembrolizumab supplied by Merck under a clinical collaboration. Reported Phase 1/2 data included 80% objective response rate and 25.5-month median progression-free survival at five-year follow-up, published in Nature Medicine and Nature Communications.

In August 2025, the company announced Phase 3 results showing 19.4 months median PFS for Cylembio plus pembrolizumab versus 11.0 months for pembrolizumab alone, with a 23% reduction in risk of disease progression or death (HR 0.77) but a p-value of 0.056, narrowly missing statistical significance. In September 2025, the FDA recommended against BLA submission, prompting approximately 50% workforce reductions. The company engaged Raymond James in January 2026 to explore strategic alternatives and ultimately filed for Chapter 7 bankruptcy in March 2026, ceasing all operations with all directors stepping down and shareholders unlikely to receive liquidation proceeds.

IO Biotech firmographics

Firmographics
Name
IO Biotech
Legal name
IO Biotech, Inc.
Website
https://iobiotech.com
Company type
Public
Founded year
2015
Operating status
Closed
Headcount range
11–50 employees
Short description
IO Biotech was a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines using its T-win platform, with lead candidate Cylembio for advanced melanoma. The company filed for Chapter 7 bankruptcy in March 2026 after the FDA rejected its BLA.
Ownership category
akta.pro rank

IO Biotech industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Therapeutic cancer vaccines
  • Immune oncology
  • Tumor microenvironment modulation
  • Off-the-shelf peptide vaccines
  • Clinical-stage biopharmaceutical

Where IO Biotech is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices3 records

Markets served

IO Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Revenue (Future): Pre-commercial stage company. Planned U.S. product launch for Cylembio was expected in 2026 prior to FDA rejection. No revenue currently generated from product sales.
  2. Debt Financing: European Investment Bank debt financing of up to €57.5 million to fund development of cancer vaccine candidates, with first disbursements expected in early 2025.
  3. Private Placement Financing: $75 million private placement financing involving new and existing investors to support ongoing clinical trials, extending cash runway into late 2025.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

IO Biotech product offering

Product offering

Core offering

IO Biotech develops off-the-shelf, immune-modulatory therapeutic cancer vaccines built on its proprietary T-win® platform. Lead candidate Cylembio (IO102-IO103 / imsapepimut and etimupepimut, adjuvanted) combines peptide epitopes targeting IDO1 and PD-L1 and was evaluated in combination with pembrolizumab in a global Phase 3 trial for advanced melanoma, with additional Phase 2 studies in NSCLC and head and neck cancer. Pipeline candidates IO112 (arginase-1) and IO170 (TGF-βL1) extend the platform to other immune-suppressive pathways.

Product overview

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win® platform. The company's lead product candidate is Cylembio (imsapepimut and etimupepimut, adjuvanted), also known as IO102-IO103, which combines two vaccines targeting IDO1 and PD-L1. The pipeline includes additional candidates IO112 (arginase-1 targeting) and IO170 (TGF-β targeting), all leveraging the T-win platform's dual mechanism of action to kill tumor cells and immune-suppressive cells in the tumor microenvironment.

Differentiator

Problem solved

Functional benefit

Brands

  • T-win: The company's proprietary immune-modulatory vaccine technology platform designed to activate T cells to target both tumor cells and immune-suppressive cells in the tumor microenvironment.
  • Cylembio

Products and services

  • Cylembio (imsapepimut and etimupepimut, adjuvanted; also known as IO102-IO103) Cylembio (IO102-IO103) is IO Biotech's lead investigational immune-modulatory, off-the-shelf therapeutic cancer vaccine combining two vaccine components: IO102 targeting the IDO1 immune-suppressive antigen and IO103 targeting PD-L1. It is designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment by stimulating T cell activation against IDO1+ and/or PD-L1+ cells, with intended use in combination with pembrolizumab for advanced melanoma, NSCLC, and head and neck cancer.
  • IO112 (Arginase-1 Vaccine) IO112 is a wholly owned IO Biotech T-win vaccine candidate designed to activate and expand T cells specific for arginase-1 positive/expressing cells in the tumor microenvironment. Arginase-1 is highly expressed in difficult-to-treat tumors including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal and prostate cancers, positioning IO112 as a potential pipeline candidate for these indications.
  • IO170 (TGF-βL1 Vaccine) IO170 is a novel T-win immune-modulatory therapeutic cancer vaccine candidate designed to target TGF-βL1-expressing cells in the tumor microenvironment. By stimulating T cell activity against TGF-βL1+ cells, the vaccine aims to modulate the TGF-β pathway and drive therapeutic benefit across tumors dependent on TGF-β signaling.

Quantifiable outcome

  • 19.4 months median progression-free survival (mPFS) vs 11.0 months for pembrolizumab alone in Phase 3 trial
  • +4 more outcomes

Companies that use IO Biotech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

IO Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IO Biotech partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Merck (MSD)coreStrategic or Co-development Partner · 3 November 2022Clinical collaboration with Merck (known as MSD outside US and Canada) to evaluate IO102-IO103 in combination with KEYTRUDA (pembrolizumab). Merck supplies pembrolizumab for clinical trials while IO Biotech sponsors the trials and maintains global commercial rights. Partnership includes Phase 3 trial (IOB-013/KN-D18) in advanced melanoma and Phase 2 basket trials in lung and head/neck cancers.
  • Herlev University Hospital / Center for Cancer Immune TherapycoreStrategic or Co-development PartnerInvestigator-initiated trial (MM1636) conducted at Copenhagen University Hospital, Herlev. Scientific co-founders Dr. Mads Hald Andersen and Dr. Inge Marie Svane serve at this institution. Publication of five-year outcomes in Nature Communications.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

IO Biotech competitors and assessment

Company assessment

Direct peers

  • Moderna: Moderna is developing mRNA-based therapeutic cancer vaccines, including personalized neoantigen programs (mRNA-4157) in melanoma in combination with Merck's pembrolizumab. Directly comparable as a clinical-stage therapeutic cancer vaccine developer targeting the same checkpoint-inhibitor combination space as IO Biotech's Cylembio.
  • BioNTech: BioNTech is a leading mRNA cancer vaccine developer with FixVac (off-the-shelf shared-antigen) and individualized neoantigen programs across melanoma and other solid tumors. Closely comparable to IO Biotech's off-the-shelf, immune-modulatory vaccine approach with multiple clinical-stage candidates.
  • Gritstone bio: Gritstone bio developed neoantigen cancer vaccines (GRANITE, SLATE) and similarly pursued first-line metastatic melanoma combinations with checkpoint inhibitors. It filed for bankruptcy in 2024 after a Phase 2 failure, making it a highly comparable cautionary precedent for IO Biotech's trajectory.
  • Bavarian Nordic: Bavarian Nordic develops therapeutic cancer vaccines including its CV301 platform targeting CEA and MUC1 antigens in combination with checkpoint inhibitors. Comparable as a clinical-to-commercial stage developer of off-the-shelf therapeutic cancer vaccines in oncology.
  • Transgene: Transgene is a French clinical-stage biotech developing therapeutic cancer vaccines using viral-vector technology (TG4050 individualized neoantigen vaccine and TG4001 HPV-targeted). Comparable as a clinical-stage developer of therapeutic cancer vaccines often combined with checkpoint inhibitors.
  • Northwest Biotherapeutics: Northwest Biotherapeutics develops DCVax, a dendritic cell-based therapeutic cancer vaccine platform for glioblastoma and other solid tumors. Comparable as a clinical-stage developer of immune-cell-based therapeutic cancer vaccines targeting solid tumors.
  • VBI Vaccines: VBI Vaccines is a clinical-stage biotech developing immunotherapeutic vaccines including eVLP-based candidates for oncology indications. Comparable as a clinical-stage therapeutic vaccine developer operating in the immune-oncology space.

Emerging players

  • Nouscom: Nouscom is a privately held biotech developing off-the-shelf, vector-based neoantigen cancer vaccines in solid tumors. Comparable emerging-stage therapeutic cancer vaccine developer using a similar off-the-shelf, combination-therapy approach as IO Biotech's Cylembio.

Broad incumbents

  • Merck & Co. (MSD): Merck is the maker of Keytruda (pembrolizumab), the checkpoint inhibitor used as both the combination partner and comparator in IO Biotech's Phase 3 trial. It is also a broader incumbent in immuno-oncology with a deep oncology pipeline and was IO Biotech's clinical-trial partner under a 2022 collaboration.
  • Bristol-Myers Squibb: Bristol-Myers Squibb is a broad incumbent in immuno-oncology with Opdivo (nivolumab) and Yervoy (ipilimumab) as foundational checkpoint inhibitors. Comparable as a leading competitor defining the treatment landscape IO Biotech's Cylembio sought to enter in first-line melanoma.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IO Biotech social profiles

Digital presence

IO Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IO Biotech leadership team

Management profile

Number of profiles

Profiles22 records

IO Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IO Biotech funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IO Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IO Biotech

What does IO Biotech do?

IO Biotech develops off-the-shelf, immune-modulatory therapeutic cancer vaccines built on its proprietary T-win® platform. Lead candidate Cylembio (IO102-IO103 / imsapepimut and etimupepimut, adjuvanted) combines peptide epitopes targeting IDO1 and PD-L1 and was evaluated in combination with pembrolizumab in a global Phase 3 trial for advanced melanoma, with additional Phase 2 studies in NSCLC and head and neck cancer. Pipeline candidates IO112 (arginase-1) and IO170 (TGF-βL1) extend the platform to other immune-suppressive pathways.

Is IO Biotech a public or private company?

IO Biotech is a public company. It is classified as public and is currently closed.

When was IO Biotech founded?

IO Biotech was founded in 2015. It employs 11 to 50 people.

Where is IO Biotech based?

IO Biotech is headquartered in Copenhagen, Denmark, in the Europe region.

How does IO Biotech make money?

Three revenue lines are on record. Product Revenue (Future) is the primary driver. The others are debt Financing and private Placement Financing.

Who are IO Biotech's main competitors?

Direct peers on record are Moderna, BioNTech, Gritstone bio, Bavarian Nordic, Transgene, Northwest Biotherapeutics and VBI Vaccines. Nouscom is listed as an emerging player. Broad incumbents are Merck & Co. (MSD) and Bristol-Myers Squibb.

Does IO Biotech have an API?

No public API is recorded for IO Biotech.

What industry is IO Biotech in?

IO Biotech's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsightDelveInsight forecasts the cancer vaccines market to grow at a 36% CAGR from 2026 to 2036, with the market size in leading markets reaching approximately $335 million in 2025. The US accounted for 87% of the 7MM market in 2025, and prostate cancer is expected to hold about 18% of the market by 2036.AJMCFrom “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 ResultsIO Biotech presented new preclinical data at the American Association for Cancer Research demonstrating that its immune-modulatory cancer vaccines, specifically IO102/IO103 and IO170, effectively activate T cells to reprogram the tumor microenvironment. The company is currently conducting a phase 3 trial for metastatic melanoma with results expected in Q3 2025, while also completing enrollment in a phase 2 basket trial for melanoma and head and neck cancers. These developments support IO Biotech's goal to file a Biologics License Application with the FDA by the end of 2025.GlobeNewswireDelisting of Securities from The Nasdaq Stock MarketNasdaq announced delisting of securities for MingZhu Logistics, Harrison Global, MSP Recovery, EPWK Holdings, Inspire Veterinary, Synlogic, Twin Hospitality, FAT Brands, Carbon Revolution, ScanTech AI, CASI Pharmaceuticals, TIAN RUIXIANG, Oak Woods, Iterum Therapeutics, IO Biotech, and QVC Group. All listed companies had suspended shares since December 2025 to April 2026.BioSpace6 biotechs that called it quits in Q1Six biotech companies closed down or wound down operations during Q1 2025, affecting at least several dozen employees, with reasons ranging from insufficient funding and failed clinical trials to regulatory challenges. The companies include Rampart Bioscience (January, ended DNA-based therapy work), Lyra Therapeutics (January, laid off 28 employees, had $22.1M cash runway), Faraday Pharmaceuticals (February, Phase 3 trial failure), EveryONE Medicines (March, cited FDA personalized medicine framework challenges), f5 Therapeutics (March, cited funding drought for early-stage biotech), and IO Biotech (March, filed Chapter 7 bankruptcy after FDA advised against submitting BLA for cancer vaccine Cylembio).Defense WorldIO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from AnalystsFive analysts currently covering IO Biotech, Inc. have assigned the stock an average consensus rating of "Reduce," with two sell ratings and three hold ratings, according to MarketBeat. The average 12-month price target is $3.50, while the stock opened at $0.05 on Friday with a market cap of $3.45 million and a notably high debt-to-equity ratio of 18.29. Multiple recent analyst actions included a downgrade from Piper Sandler and Morgan Stanley, though Wall Street Zen issued an upgrade during the period reviewed.BioSpaceIO Shuts Down Following Regulatory RoadblocksDanish biotech company IO Biotech is shutting down and filing for Chapter 7 bankruptcy after the FDA rejected its approval application for cancer vaccine Cylembio in September 2025. The rejection followed a Phase 3 trial in advanced melanoma that narrowly missed its primary endpoint, showing a 23% reduction in risk of disease progression or death with a p-value of 0.056. The company had already significantly reduced its workforce to around 39 employees before implementing additional layoffs, and all directors stepped down as part of the bankruptcy filing, with shareholders unlikely to receive any payment.FierceBiotech‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1According to Fierce Biotech's layoff tracking, 33 biopharma companies announced layoffs or shutdowns in Q1 2026, representing a significant decline from 63 such rounds in Q1 2025 and continuing a downward trend first identified in September 2025. Major restructuring efforts continued at Takeda (634 U.S. jobs), Evotec (800 employees and 4 site closures over two years), and Viatris (approximately 10% of its 32,000-person global workforce), while several smaller biotechs including IO Biotech, f5 Therapeutics, and Nido Biosciences shuttered entirely. Industry experts suggest the reduced pace reflects companies having completed overdue strategic course corrections, though wildcard factors including AI disruption and tariff impacts could still affect 2026 hiring trends.FiercePharma‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1Biopharma layoffs slowed to 33 companies announcing cuts or shutdowns in Q1 2026, roughly half the 63 seen in Q1 2025, with experts attributing this to companies having completed overdue strategic restructuring after years of cost-cutting. Takeda unveiled plans to cut 634 U.S. jobs as part of restructuring to save $1.26 billion annually, while several biotechs including Theravance Biopharma, Gossamer Bio, and IO Biotech faced severe workforce reductions or closures following clinical trial failures. Industry observers expect the lower layoff intensity to continue through 2026, though uncertainty around AI and tariff impacts could introduce unexpected disruptions.BenzingaWhy Are Shares Of IO Biotech Plummeting?IO Biotech, Inc. filed for Chapter 7 bankruptcy in Delaware and will cease all operations, causing its shares to plummet approximately 73% to around $0.046. The stock is trading 81.5% below its 20-day moving average and 91.6% below its 100-day SMA, with shares down 96.09% over the past 12 months. The bankruptcy is being treated as an insolvency event rather than routine small-cap de-risking, with the stock pressing toward new lows and no clear technical support defined.FierceBiotechStill reeling from FDA refusal, IO Biotech surrenders to bankruptcyIO Biotech, a Danish biotech company, has filed for bankruptcy and ceased all operations after the FDA advised against submitting its cancer vaccine Cylembio for approval following a failed Phase 3 trial where it missed statistical significance against Merck & Co.'s Keytruda in treating melanoma. The company responded by halving its workforce and exploring strategic alternatives, but was unable to survive, with a trustee now appointed to liquidate its assets. The shutdown comes amid a wave of early-stage biotech failures, with Lipella Pharmaceuticals and f5 Therapeutics also closing on the same day.